• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Learn Why The Bull Case For HCA Healthcare Stock Could Change Following Uninsured Patient Growth

    Simply Wall St·11/09/2026 22:22:05
    Listen to the news
    • HCA Healthcare reported third quarter 2026 sales of US$19,849 million and net income of US$1,579 million, alongside completed fixed income offerings that included 6.500% notes due 2056 and 5.2% notes due 2028, plus a declared US$0.78 quarterly dividend and continued share repurchases.
    • Management flagged growing uninsured patient volumes linked to changes in public health insurance exchange coverage as a pressure point on margins, while the business continues returning capital through dividends and buybacks and adds long dated unsecured debt to its capital structure.
    • This article examines how HCA Healthcare's investment narrative is being tested by higher uninsured volumes highlighted on the third quarter earnings call.
    Seize this chance to stress test HCA Healthcare against peers by scanning a curated set of resilient balance sheet plays with the list of solid balance sheet and fundamentals (25 results).

    HCA Healthcare Investment Narrative Recap

    To own HCA Healthcare, you need to be comfortable with a hospital operator that leans on insured volume growth, cost discipline and a large capital program while absorbing policy driven coverage shifts. The analyst consensus narrative on Simply Wall St assumes HCA keeps offsetting payer mix pressure with expansion of beds and outpatient facilities plus cost efficiency work.

    The third quarter update and commentary on higher uninsured volumes put that payer mix assumption under real strain. Management is now juggling rising self pay exposure, soft outpatient surgical activity and evolving Medicaid and exchange dynamics. For the near term, the most important swing factor and risk stays the same: stabilising coverage and protecting margins.

    The recent fixed income offerings, including the US$750 million 6.500% notes due 2056 and US$500 million 5.2% notes due 2028, matter because they shape how HCA Healthcare funds that multi year capacity build while managing a high debt load and negative shareholders equity. These bonds are senior, unsecured and callable, so they sit squarely in that capital structure discussion.

    For you as a shareholder, the key question is how comfortably the business can service and refinance this debt while dealing with uninsured volume growth and policy risk around Medicaid and exchange support. Execution on cost control, ambulatory expansion and workforce investments now has to work alongside disciplined balance sheet management rather than in isolation.

    HCA Healthcare's narrative projects US$89.9b revenue and US$6.9b earnings by 2029. This implies 4.5% yearly revenue growth and an earnings increase of about US$0.1b from US$6.8b today.

    Uncover why HCA Healthcare's fair value indicates a 4% potential downside to its current price, which leaves little room for error.

    NYSE:HCA 1-Year Stock Price Chart
    NYSE:HCA 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the most optimistic analysts focus on HCA Healthcare’s AI and cost resiliency program as the real swing factor, rather than payer mix. Before this debt issuance and the coverage news, that group was modeling about US$90.8b of 2029 revenue and US$7.7b of earnings. Those expectations may shift, so consider both narratives before deciding what seems reasonable.

    Explore 3 other HCA Healthcare fair value estimates, including one that suggests there could be as much as 80% upside from the current price.

    Decide For Yourself

    Don’t just follow the ticker; dig into the data and build a conviction that’s truly your own.

    Looking for more HCA Healthcare investment ideas?

    If the HCA Healthcare story has you rethinking your portfolio mix, it can help to widen the lens and compare it with other businesses that share some of the qualities you care about most.

    • Prefer to back financially robust operators that aim to protect capital first? Start by scanning a curated 31 resilient stocks with low risk scores that may help you focus on resilience over excitement.
    • Interested in stronger fundamentals combined with potential mispricing? Spot opportunities using a carefully filtered 40 high quality undervalued stocks that highlights businesses where quality and valuation both matter.
    • Want to broaden your watchlist beyond the usual large caps? Use a targeted 19 high quality undiscovered gems to surface under-followed ideas with healthier balance sheets and cleaner fundamentals.